Tasly Pharmaceutical Group Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Tasly Pharmaceutical Group şirketinin toplam hissedar öz sermayesi CN¥13.0B ve toplam borcu CN¥2.1B olup, bu da borç-öz sermaye oranını 16.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥16.8B ve CN¥3.8B dir. Tasly Pharmaceutical Group 'in FAVÖK'ü CN¥1.4B faiz karşılama oranı -44.7 dur. Şirketin CN¥5.0B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

16.2%

Borç/özkaynak oranı

CN¥2.11b

Borç

Faiz karşılama oranı	-44.7x
Nakit	CN¥4.97b
Eşitlik	CN¥13.02b
Toplam yükümlülükler	CN¥3.82b
Toplam varlıklar	CN¥16.83b

Son finansal sağlık güncellemeleri

Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?

Jul 22

Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Mar 15

Recent updates

Investors Continue Waiting On Sidelines For Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Nov 17

Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?

Jul 22

Estimating The Intrinsic Value Of Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Jun 13

The Market Doesn't Like What It Sees From Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Earnings Yet

May 13

Tasly Pharmaceutical Group's (SHSE:600535) Solid Earnings Have Been Accounted For Conservatively

Apr 26

Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Mar 15

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 600535 'nin kısa vadeli varlıkları ( CN¥9.1B ) kısa vadeli yükümlülüklerini ( CN¥3.4B ) aşıyor.

Uzun Vadeli Yükümlülükler: 600535 şirketinin kısa vadeli varlıkları ( CN¥9.1B ) uzun vadeli yükümlülüklerini ( CN¥456.4M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 600535 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 600535 'nin borç/öz sermaye oranı son 5 yılda 71% seviyesinden 16.2% seviyesine düştü.

Borç Kapsamı: 600535 'nin borcu işletme nakit akışı ( 126.6% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 600535 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

Tasly Pharmaceutical Group Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?

Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Recent updates

Investors Continue Waiting On Sidelines For Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Consensus EPS estimates fall by 14%

Third quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.22 in 3Q 2023)

Upcoming dividend of CN¥0.26 per share

Tasly Pharmaceutical Group Co., Ltd to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 18%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 23% overvalued

Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?

Tasly Pharmaceutical Group Co., Ltd to Report First Half, 2024 Results on Aug 24, 2024

Price target increased by 8.7% to CN¥16.17

Estimating The Intrinsic Value Of Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Now 20% overvalued

Dividend of CN¥0.33 announced

The Market Doesn't Like What It Sees From Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Earnings Yet

First quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.18 in 1Q 2023)

Tasly Pharmaceutical Group's (SHSE:600535) Solid Earnings Have Been Accounted For Conservatively

Price target decreased by 7.0% to CN¥13.88

Tasly Pharmaceutical Group Co., Ltd, Annual General Meeting, May 08, 2024

Now 21% undervalued after recent price drop

Tasly Pharmaceutical Group Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024

Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Investor sentiment improves as stock rises 16%

Now 22% undervalued after recent price drop

ShuYu Civilian Pharmacy Corp., Ltd. Scraps Plan to Buy Stake in Tasly Pharmaceutical's Two Units

Third quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.047 in 3Q 2022)

Tasly Pharmaceutical Group Co., Ltd to Report Q3, 2023 Results on Oct 28, 2023

Price target increased by 10% to CN¥12.76

Price target decreased by 13% to CN¥10.64

Consensus EPS estimates fall by 19%

Second quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.10 in 2Q 2022)

Now 21% undervalued after recent price drop

Consensus EPS estimates increase by 12%

Tasly Pharmaceutical Group Co., Ltd to Report First Half, 2023 Results on Aug 26, 2023

Now 21% undervalued after recent price drop

Now 21% undervalued

Price target increased by 9.3% to CN¥12.10

Price target increased by 7.3% to CN¥11.79

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 8.0% to CN¥10.99

Consensus EPS estimates fall by 35%

Investor sentiment improves as stock rises 16%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.047 (vs CN¥0.32 in 3Q 2021)

Price target decreased to CN¥10.19

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.45 in 2Q 2021)

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to CN¥14.34

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Consensus forecasts updated

Consensus forecasts updated

Price target increased to CN¥16.52

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall to CN¥1.03

Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.27 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.26 in 2Q 2020)

Consensus revenue estimates fall to CN¥7.67b

First quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.20 in 1Q 2020)

Tasly Pharmaceutical Group Co., Ltd to Report Fiscal Year 2020 Results on Mar 30, 2021

Tasly Pharmaceutical Group Co., Ltd(XSSC:600535) dropped from S&P Global BMI Index

New 90-day low: CN¥13.57

New 90-day low: CN¥14.49

Price target raised to CN¥19.43

New 90-day low: CN¥14.83

New 90-day low: CN¥16.61

Earnings beat expectations, revenue disappoints

New 90-day high - CN¥19.62

Earnings released

Chongqing Pharmaceutical (Group) Co., Ltd. completed the acquisition of Tianjin Tasly Medicine Distribution Group CO.,LTD. from a group of shareholders.